FDA Panel Examines Path to Testosterone Treatment for Menopausal Women

September 17, 2026

Clinicians, researchers, and a patient representative gathered September 17 at FDA's White Oak Campus to examine the evidence needed to develop a testosterone treatment for menopausal women. The panel, moderated by FDA's Dr. Christine Pham Nguyen, was part of a public workshop intended to identify research gaps and inform drug development as off-label use continues.

For Tagline Strategies, the discussion reinforced an early priority for developers: define the condition a product will treat and how its benefits will be measured. The meeting itself did not change approval standards.

Following individual presentations, the speakers gathered for a moderated panel discussion on the evidence, clinical challenges, and research needed to advance treatment.

Panel Discussion

Dr. Margaret E. Wierman, a University of Colorado professor, distinguished the evidence supporting treatment of hypoactive sexual desire disorder—persistent low sexual desire that causes distress—from less-established uses involving energy, mood, and cognition. She also cautioned against describing testosterone therapy as hormone replacement given the available evidence.

Dr. James A. Simon, medical director of IntimMedicine Specialists and a George Washington University clinical professor, emphasized the limits of laboratory results in judging a patient's response. "I treat patients. I don't treat lab values," he said.

Dr. Rajita Patil, director of UCLA's Comprehensive Menopause Program, called for larger studies that include excluded patient groups and better measures of benefit, such as improved quality of life or reduced distress. She also identified the lack of a standardized treatment as a major obstacle to producing reliable evidence.

Dr. Pelin Batur of the Cleveland Clinic described the practical burden of prescribing without an FDA-approved testosterone product designed for women, including variable dosing and repeated testing. "We're doing a lot of number chasing right now, and that's because we don't have an FDA-regulated product," she said.

Dr. Rachel Rubin, a urologist and sexual medicine specialist, pressed for research that captures the improvements women seek in daily life. "It's really hard to capture NFLM 'not feeling like myself' in an FDA endpoint," she said.

Patient representative Susan Lake urged women to seek guidance from sexual health specialists and emphasized the need for better clinician education. She identified availability, cost and timely access as priorities for treatment.

Nguyen acknowledged that some safety questions would remain even if a product reached the market. "We won't know the entire safety profile of a drug when we approve it," she said.

Tagline's Analysis

Tagline recommends that developers plan early for clinician and patient education. An approved product would enter a market already shaped by off-label prescribing, making clear guidance on dosing, monitoring, and remaining safety questions essential.

Back to All News
Tagline’s David Small poses with workshop panelist Dr. Rachel Rubin, a urologist and sexual medicine specialist who provided attendees the clinician’s perspective regarding testosterone use in menopausal women.

Stay in the Know with
Our Latest Insights

Sign up for Tagline’s Newsletter, a digest of regulatory, policy, and communications developments shaping the industries we serve. We promise not to spam you! Our aim is to publish a quarterly newsletter with special features once in a while.

Sign Up